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Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease associated with accelerated atherosclerosis and increased
risk of cardiovascular (CV) disease. AS patients also display a high prevalence of features clustered under the name of metabolic
syndrome (MeS).Anti-TNF-𝛼 therapywas found to be effective to treatASpatients by suppressing inflammation and also improving
endothelial function. Previously, it was demonstrated that a short infusion of anti-TNF-𝛼monoclonal antibodyinfliximab induced
a rapid and dramatic reduction in serum insulin levels and insulin resistance along with a rapid improvement of insulin sensitivity
in nondiabetic AS patients. The role of adipokines, MeS-related biomarkers and biomarkers of endothelial cell activation and
inflammation seem to be relevant in different chronic inflammatory diseases. However, its implication in AS has not been fully
established. Therefore, in this review we summarize the recent advances in the study of the involvement of these molecules in CV
disease or MeS in AS. The assessment of adipokines and biomarkers of endothelial cell activation and MeS may be of potential
relevance in the stratification of the CV risk of patients with AS.
1. Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
rheumatic disease, which mainly affects the axial joints,
including the spine, sacroiliac joints, and entheses, but it
may also involve peripheral joints [1]. Along with disease
progression, inflamed joints tend to fuse (ankylosis) and there
is also an ossification of the inflamed entheses, often leading
to a loss of the well-known flexibility of the spine. AS is
more prevalent in men than in women and usually appears
around the third decade of life [1]. Moreover, extra-articular
manifestations such as uveitis, psoriasis, or osteoporosis are
frequently associated with this rheumatologic disease [2].
As observed in other rheumatologic diseases, such as
rheumatoid arthritis (RA), AS patients disclose an increased
risk of cardiovascular (CV) disease when compared to
general population, being CV diseases one of the main
causes of mortality in these patients [1]. Furthermore, an
accelerated atherosclerotic process in these patients has also
been reported [3].
AS patients also display a high prevalence of features
such as obesity, dyslipidemia, hypertension, alterations in
glucose metabolism, and insulin resistance (IR), which are
clustered under the name of metabolic syndrome (MeS)
[4]. Interestingly, individuals that suffer MeS also exhibit
a dysregulation of adipokines, which are highly bioactive
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substances secreted by adipocytes and immune cells and that
are involved not only in metabolic functions but that also
play an immunomodulatory role [5, 6]. This dysregulation
leads to metabolic disorders such as IR [5], an essential
feature of MeS that has been associated with inflammation
[7]. In addition, multiple evidences show that IR promotes
endothelial dysfunction [8, 9], an early key step in the
atherogenic process which appears even before the structural
changes associated with this process [10].
Regarding therapeutic approaches aimed to treatAS, anti-
TNF-𝛼 therapy was found to be effective to treat patients with
this disease and other types of spondyloarthritis [11–13]. Anti-
TNF-𝛼 agents neutralize this cytokine leading to suppression
of inflammation and, consequently, to a reduction of disease
activity [14]. Moreover, it was demonstrated that this biologic
therapy improves endothelial function in AS patients [15].
For the purpose of this review, we took advantage of
data obtained from a series of 30 nondiabetic AS patients
undergoing anti-TNF-𝛼 therapy with the chimeric anti-TNF-
𝛼monoclonal antibody infliximab [16]. At the time of assess-
ment, these patients had been treated with this biologic agent
for a median of 23 months. Since IR promotes endothelial
dysfunction [8, 9], while anti-TNF-𝛼 treatment improves
endothelial function in AS patients [15], our first objective
was to evaluate short-term insulin response following anti-
TNF-𝛼 infliximab therapy. We observed that our patients
experienced a rapid and dramatic reduction in serum insulin
levels and IR along with rapid improvement of insulin
sensitivity after a single administration of infliximab [16].
This observation had previously been described in patients
with RA undergoing anti-TNF-𝛼 infliximab therapy [17, 18].
Considering these results, we decided to further evaluate
the short-term effect of anti-TNF-𝛼 therapy in our series of
AS patients on periodical treatment with infliximab on MeS-
related biomarkers, adipokines, and biomarkers of endothe-
lial cell activation and inflammation. Figure 1 depicts the
pathophysiologic context that encompasses all the molecules
reviewed in this paper. Furthermore, themain results derived
from these studies on the effect of an infliximab infusion are
summarized in Table 1.
In this review, recent advances in the study of the involve-
ment of these molecules in CV disease or MeS in AS patients
are discussed, along with the possible link between these




As previously mentioned, AS patients frequently display
features ofMeS [4].Therefore, the study of potential biomark-
ers involved in the development of such features and its
association with the pathogenesis of this spondyloarthritis
could give us hints for the outcome and treatment of these
patients.
2.1. Ghrelin. Ghrelin, a peptide predominantly expressed
in the stomach, is the endogenous ligand for the growth
Table 1: Effect of an infusion of the anti-TNF-𝛼 monoclonal
antibody infliximab on MeS-related biomarkers, biomarkers of
endothelial cell activation and inflammation, and adipokines in a




Reduction in serum insulin levels and IR
Improvement of insulin sensitivity
Reduction of RBP-4 serum levels






Reduction of Angpt-2 serum levels
Reduction of OPN serum levels
No significant change on ADMA and GSN
serum levels
No significant reduction on OPG plasma
levels
Adipokines
No significant change in the levels of the
different adipokines (adiponectin, resistin,
leptin, visfatin, and apelin)
hormone secretagogue receptor (GHS-R), which regulates
food intake and GH expression [19] and also acts as an
anti-inflammatory molecule [20]. Previously, low levels of
this peptide have been observed in obese individuals [21], a
condition directly associated with hyperinsulinemia and IR.
In our series we disclosed a significant correlation between
ghrelin and IR and insulin sensitivity [22]. Similar results had
previously been reported in individuals without rheumatic
diseases [23, 24].However, since only 10%of our patientswere
obese, possibly other mechanisms different from obesity may
account for our findings. Furthermore, in this study we also
observed a positive correlation between ghrelin and resistin,
which is in accordance with their role in glucose homeostasis
and the inflammatory process [22].
To our knowledge, the only previous study performed to
evaluate ghrelin levels in AS patients was the one reported by
Toussirot et al. [25]. However, in that study they described
higher levels of ghrelin in AS patients when compared to
controls.These results seem to be unexpected, since ghrelin is
known to inhibit the production of inflammatory cytokines
[20]. In line with this, RA patients show decreased ghrelin
levels when compared to healthy controls [26]. Therefore,
further studies are needed to elucidate whether the different
inflammatory burden in RA and AS may account for these
contradictory results.
We previously reported a significant elevation of ghrelin
serum concentration upon a single infliximab infusion in RA
patients with severe disease who despite receiving this anti-
TNF-𝛼 agent had active disease with persistent elevation of
laboratorymarkers of inflammation [27]. However, following
a single infusion of infliximab, when we compared ghrelin
levels found immediately before and after an infliximab
infusion (the drug was administered in the fasting state, in
saline solution over 120 minutes), we only disclosed a mild
but not significant increase of ghrelin serum concentration
in patients with AS [22]. These disparate results may be due
to the absence of severe disease in our series of patients of AS






























Figure 1: Pathophysiologic context that encompasses all the molecules reviewed in this paper. Ankylosing spondylitis patients display a
high incidence of features clustered under the name of metabolic syndrome, which include obesity, dyslipidemia, hypertension, alterations
in glucose metabolism, including insulin resistance, and also a dysregulation of adipokines. Moreover, all these pathologic features are
associated with inflammation and lead to endothelial dysfunction and, consequently, to an enhanced risk of CV disease (mainly due
to accelerated atherosclerosis) and CV death in these patients. Anti-TNF-𝛼 treatment not only suppresses inflammation, reducing thus
ankylosing spondylitis activity, but it also improves endothelial function in these patients. The molecules that will be reviewed in this paper
are included in this figure inside blue dashed boxes. ∗Anti-TNF-𝛼 improves insulin resistance and endothelial function and also reduces
inflammation. ADMA: asymmetric dimethylarginine; Angpt-2: angiopoietin-2; OPG: osteoprotegerin; OPN: osteopontin; RBP-4: retinol
binding protein-4.
at the time of assessment. It was not the case in RA patients
undergoing infliximab therapy as the series of patients with
RA still had active disease despite periodical treatment with
this TNF-𝛼 inhibitor.
2.2. Retinol Binding Protein-4 (RBP-4). Retinol binding
protein-4 (RBP-4) is another metabolic syndrome-related
biomarker, also considered a new potential cardiometabolic
risk factor. This proinflammatory protein is mainly released
by adipocytes but also expressed in liver and macrophages
[28] and has been associated with IR in individuals with obe-
sity, impaired glucose tolerance or type 2 diabetes mellitus,
and nonobese subjects with or without family history of type
2 diabetes [29–31]. In our study, we disclosed a marginally
significant correlation between RBP-4 serum levels and IR
and a correlation with systolic blood pressure. Besides, when
our AS patients where stratified according to sex, men
showed higher levels of this protein than women [32], which
was in keeping with the results previously reported by Gavi
et al. [30]. More importantly, when we evaluated the effect of
a single infusion of anti-TNF-𝛼 infliximab on RBP-4 levels,
we observed a statistically significant reduction in its levels.
Furthermore, this change was more evident in those patients
who had a higher IR index [32].
A former study disclosed that AS patients may have lower
RBP-4 serum levels than controls [33]. However, when we
compared our patients with healthy controls we did not find
significant differences in RBP-4 serum levels [32]. The low
disease activity at the time of study in our series of AS patients
may explain the absence of differences in RBP-4 serum levels
when compared with controls.
3. Adipokines in AS
Immune system and metabolism are linked through a net-
work of soluble mediators widely known as adipokines,
which take part in both metabolic and immunomodulatory
functions [6]. Although the role of adipokines seems to
be relevant in many chronic inflammatory diseases, the
implication in AS has not been completely elucidated.
3.1. Adiponectin. Adiponectin is an adipokine mainly pro-
duced by adipocytes but that can also be found in endothelial
cells, skeletalmuscle cells, and cardiacmyocytes [6]. Circulat-
ing adiponectin levels inversely correlate with adiposity [5],
which suggests that this adipokine exerts a protective func-
tion against CV disease and obesity. Adiponectin increases
fatty acid oxidation and reduces the synthesis of glucose in
the liver and other tissues [34]. Depending on the context,
this adipokine can have pro- or anti-inflammatory functions.
Unlike observations in nonrheumatic patients, RAhigh levels
of this adipokine have been reported in the inflamed joints,
since it promotes matrix degradation [35]. However, results
obtained in AS are contradictory. Some groups did not find
differences in serum adiponectin levels between AS patients
with active disease and controls [25], while others found
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significantly higher levels of this adipokine in a series of AS
patients under treatment with infliximab, when compared
with controls [36].
In our series ofAS patientswe found a positive correlation
between adiponectin serum levels and insulin sensitivity,
suggesting that low circulating adiponectin concentrations
may be associated withmetabolic abnormalities that promote
CV disease in AS [37]. The effect of adiponectin on insulin
sensitivity is mediated in part by its ability to activate
signaling pathways that lead to glucose uptake in muscle
tissue and the inhibition of gluconeogenesis in the liver
[38]. Furthermore, AS patients with hip involvement or
synovitis and/or enthesitis in other peripheral joints had
higher levels of adiponectin than those who did not have
these complications [37]. These results are in keeping with
the proinflammatory role described for adiponectin in the
joints of RA patients [35]. Therefore, higher adiponectin
levels might help to establish a subgroup of AS patients with
predominant peripheral involvement.
As observed in RA patients undergoing anti-TNF-𝛼
infliximab therapy [39], a single infusion of this biologic agent
did not lead to significant changes in the serum levels of
adiponectin in patients with AS [37].
3.2. Resistin. Resistin is another proinflammatory adipokine
mainly produced by monocytes and macrophages [40].
Proinflammatory factors such as TNF-𝛼 and IL-6 induce its
expression [41]. Interestingly, a positive correlation between
serum resistin and C-reactive protein (CRP) and erythrocyte
sedimentation rate (ESR) has been observed in RA patients
[42–44]. Moreover, resistin serum levels have been found
increased in synovial fluid of RA patients [45]. In AS patients,
likewise, higher levels of this adipokine have been observed
as compared to controls [46].
In our cohort of AS patients treated with the TNF-𝛼
antagonist infliximab we did not observe any correlation
between resistin concentration and disease activity or lab-
oratory markers of inflammation, probably due to the low
inflammatory burden as a result of prolonged treatment with
anti-TNF-𝛼 [37]. These results are in agreement with those
obtained by Kocabas et al., who did not find any correlation
between resistin concentration and ESR, CRP, or BASDAI
in their series of AS patients [46]. Once again, the lower
inflammatory burden in our AS patients due to prolonged
treatment with this biologic therapy could also explain the
lack of effect observed after a single infusion of infliximab on
resistin concentration [37].
3.3. Leptin. Leptin also belongs to the group of proinflam-
matory adipokines, being produced by many cell types,
including adipocytes [47].This adipokine is involved in body
weight regulation, since it inhibits food intake and stimulates
energy expenditure [48]. Moreover, a proatherogenic role for
leptin has been described [49]. Leptin induces the production
of the proinflammatory cytokines IL-6, IL-12, and TNF-𝛼
by monocytes and macrophages [50], while it suppresses
the production of IL-4, an anti-inflammatory cytokines [51].
Leptin levels are regulated by inflammatory mediators such
as TNF-𝛼 and IL-1 [52]. While in RA leptin has a clear proin-
flammatory role, showing increased levels in patients when
compared with healthy controls [53], the results obtained for
this adipokine in AS are contradictory. Some groups found
increased leptin levels in AS patients with active disease
when compared to controls [54], while others found lower
circulating levels of this adipokine than in controls [25, 55].
In contrast to previous reports which found a corre-
lation between leptin levels and BASDAI in a series of
AS patients [54], in our AS cohort, we did not observe
any correlation between the levels of this adipokine and
clinical and laboratory parameters of disease activity and
inflammation [56]. Similar results were obtained in a series of
RA patients undergoing periodical anti-TNF-𝛼 therapy [57].
Furthermore, as previously described [58], when our series
of AS patients were stratified according to sex, we disclosed
higher levels of leptin in women [56].
Whenwe analyzed the effect of TNF-𝛼 blockade on circu-
lating leptin levels, we found that they were not significantly
altered [56]. Similar results were obtained by other groups,
either in AS patients after 6 months of infliximab treatment
[36] or in RA patients undergoing 2 weeks and 6 months
TNF-𝛼 blockade [59].
3.4. Visfatin. Visfatin, also known as pre-B cell colony-
enhancing factor or PBEF, is a proinflammatory adipokine
with ubiquitous expression [60]. Visfatin was reported to
act as an insulin-mimetic adipokine [61]. This adipokine
positively correlates with visceral fat [62] and has also been
described as an immunomodulatory molecule [63, 64]. In
fact, visfatin can inducemonocytes to produce proinflamma-
tory cytokines such as IL-1, TNF, and IL-6 [64]. Previously,
increased levels of this adipokine have been observed in
patients with RA [53] when compared to controls. However,
to our knowledge, in addition to our study [56], the only
previous study performed in AS patients was performed
by Hulejová et al. [65]. In that study, which included AS
patients with mild to moderate disease, no correlation was
found between visfatin levels and disease activity, functional
status, or acute-phase reactants [65]. Similarly, in our series
of AS patients on periodical treatment with the anti-TNF-
𝛼-blocker infliximab, we could not find correlation between
serum visfatin levels and clinical and laboratory parameters
of disease activity and inflammation [56]. This was also
the case for RA patients undergoing anti-TNF-𝛼 infliximab
therapy [66].
Although we could not find association between visfatin
serum levels and metabolic syndrome in RA patients with
severe disease undergoing anti-TNF-𝛼 therapy [66], we
observed a positive correlation between visfatin serum levels
and IR in AS [56]. A former study performed in lean women
with polycystic ovary syndrome obtained similar results [67].
However, in our series of AS patients visfatin levels did not
change upon infliximab administration [56].
3.5. Apelin. Apelin is a quite recently new adipokine pro-
duced by diverse cell types, including adipocytes and
endothelial cells [68].This adipokine is considered a potential
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biomarker for CV disease risk since it stimulates nitric oxide
(NO) release and, therefore, triggers arterial vasodilation
[69]. Moreover, insulin directly upregulates the expression
of apelin [70], making this adipokine an attractive candidate
to be studied in metabolic disorders such as type-2 diabetes.
Furthermore, low apelin levels have been associatedwith high
LDL levels [71] and biomarkers of endothelial cell activation
such as VCAM-1 and E-selectin correlated to apelin levels
[72].
It has been postulated that apelin may have a role in
the pathogenesis of the CV disease, since low levels of this
adipokine have been observed in patients with ischemic
heart disease [73]. However, contradictory results have been
reported in patients with type 2 diabetes mellitus. In this
regard, in a study fasting plasma apelin levels correlated
positively with IR in patients with type 2 diabetes mellitus
[74], while in another study plasma apelin levels were reduced
in newly diagnosed and untreated patients with type 2
diabetes mellitus [75].
di Franco et al. measured apelin levels in early stage RA
patients and found that they were lower than those observed
in controls [76], suggesting a potential involvement of apelin
in the pathogenesis of the rheumatic diseases. However,
regarding AS, there are no previous reports performed to
evaluate the levels of this adipokine in this disease. In a
study of our group, apelin levels showed no association with
markers of disease activity or MeS in patients with AS [77].
In line with our results, Ferraz-Amaro et al. did not find any
correlation between the levels of apelin in RA patients treated
with anti-TNF-𝛼 and BMI or IR [78].
In a further step, we analyzed the potential effect of
anti-TNF-𝛼 infliximab treatment on apelin concentration
in our series of AS patients. We found that even after the
administration of a single dose of infliximab apelin serum
levels were reduced, this decrease did not achieve statistical
significance [77]. Similar results were previously described
in RA patients after 12 months of anti-TNF-𝛼 treatment
[78] or after 12 months of treatment with disease modifying
antirheumatic drugs [76].
4. Biomarkers of Endothelial Cell Activation
and Inflammation
In physiological conditions, NO acts as an anti-inflammatory
molecule, maintaining the vascular wall in a quiescent state,
also avoiding cellular proliferation. However, in the presence
of inflammation or CV risk factors such as hypertension,
hypercholesterolemia, or diabetes, the quiescent endothe-
lium can switch to an activated phenotype. This leads to
the secretion of proinflammatory factors such as cytokines
and adipokines, to the expression of adhesion molecules
for the recruitment of inflammatory cells to the vascular
wall and to the generation of reactive oxygen species [79].
This pathological inflammatory condition also leads to a
reduction in the release of NO into the arterial wall, either
affecting its synthesis or due to oxidative inactivation of
NO [80, 81], which further enhances the inflammatory
status and maintains the endothelial activated phenotype
[79].
Many biomarkers of endothelial cell activation and
inflammation may be potentially used by clinicians to make
an early diagnosis of CV disease and MeS. The implication
of these biomarkers in the pathogenesis of the rheumatic
diseases is also an issue of potential interest. However, as
previously mentioned for adipokines, studies performed on
AS patients are limited.
4.1. Asymmetric Dimethylarginine (ADMA). Asymmetric
dimethylarginine (ADMA) is an endogenous inhibitor of the
nitric oxide synthase (NOS), causing therefore a reduction in
NO production and leading to endothelial dysfunction and
CV events [82]. Consequently, ADMA has been proposed as
a biomarker for endothelial dysfunction and a risk factor for
CV disease [82, 83]. Furthermore, increased levels of ADMA
have been associated with hypertension [84], hypertriglyc-
eridemia [85], hypercholesterolemia [86], diabetes mellitus
[87], and IR [88], as well as with inflammatory diseases such
as RA [76] and AS [89–91].
We found higher concentrations of ADMA in AS patients
with hypertension [92]. Unexpectedly, we observed a sig-
nificant negative correlation between ADMA levels and
total cholesterol (TC) and LDL-cholesterol in AS [92],
which apparently seems to contradict previous results that
associated high ADMA levels with patients with hyperc-
holesterolemia [86]. We think that this negative association
betweenADMAandTC andLDL-cholesterolmight probably
be the result of the long-term treatment with anti-TNF-𝛼
in our series of AS patients (almost 2 years), which may
have led to a reduction of the inflammatory burden in these
patients [14] along with complex lipidic changes [93, 94].
With respect to this, our series of patients with AS were in a
state of low disease activity, with low levels of CRP, showing a
BASDAI less than 3, which is indicative of a favorable disease
activity state [92]. This could be the reason why we could not
see statistically significant associations between CRP/disease
activity markers and ADMA levels in our series of patients.
Furthermore, we did not observe any change on ADMA
levels after a single infusion of anti-TNF-𝛼 [92]. This was in
accordance with previous studies that described no effect on
ADMA concentration following long-term TNF-𝛼 blockade
[95, 96].
4.2. Angiopoietin-2 (Angpt-2). Angiopoietin-2 (Angpt-2) is a
proinflammatory marker of endothelial cell activation that
is involved in angiogenesis and makes the endothelium
responsive to inflammatory cytokines [97]. Angpt-2 levels
have been found increased in recent onset RA patients with
CV disease when compared with those without CV disease
[97], which suggests that it could be a potential biomarker
for the development of CV disease. Interestingly, a recent
study of our group disclosed a correlation between age at
the time of disease onset in patients with RA and Angpt-2
levels [98]. More importantly, after adjustment for sex, age
at RA diagnosis,and CV risk factors, Angpt-2 levels were
higher in RA patients with CV disease than in RA patients
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without CV complications [98]. Interestingly, in our series of
AS patients undergoing infliximab therapy, we also found an
association between Angpt-2 serum levels and the age at the
onset of symptoms of AS, as well as a marginally significant
association with disease duration [99].
It has been reported that Angpt-2 promotes the proin-
flammatory activation of humanmacrophages in RA synovial
tissue and that the neutralization of this molecule in an in
vivo model of RA decreased disease severity, inflammation,
neovascularisation, and joint destruction [100]. In line with
this observation, we disclosed that a single infusion of anti-
TNF-𝛼 infliximab was associated with a dramatic reduction
of Angpt-2 serum levels [99], possibly as part complex
mechanisms leading to a reduction of the risk of CV events
associated with this intervention in patients with chronic
inflammatory diseases [101].
4.3. Osteopontin (OPN). Osteopontin (OPN) is another
biomarker of atherosclerosis, synthesized by osteoclasts,
osteoblasts, chondrocytes, and by cells of the immune system
[102, 103]. This protein has pleiotropic functions such as
cellular adhesion,migration, angiogenesis, and inflammation
[102, 104]. High OPN levels have been proposed to pro-
mote the development of atherosclerotic lesions [105] and
atherosclerotic plaque rupture, acting as a chemotactic factor
for inflammatory cells and leading thus to plaque rupture
[106].
In a previous study performed by Choi et al., OPN levels
were increased in AS when compared to healthy controls
[102]. However, we did not observe significant differences
in the levels of OPN between AS patients undergoing anti-
TNF-𝛼 therapy and controls [107]. These different results
may be due to the long-term treatment with anti-TNF-𝛼
therapy that our AS patients had received at the time of
the study. It is possible that prolonged anti-TNF-𝛼 blockade
may lead to reduction of the inflammatory burden and,
therefore, to a reduction of OPN concentrations. In this
regard, OPN levels observed in our cohort of AS patients
and in the healthy matched controls were very similar to
those observed in the control group reported by Choi et al.
[102].
Interestingly, in our series of AS patients we found a
positive correlation between serum levels of OPN andAngpt-
2 [107]. Since, as described in the previous section, Angpt-2
is a marker of endothelial cell activation involved in angio-
genesis, making the endothelium responsive to inflammatory
cytokines [97], while OPN is also involved in the develop-
ment of atherosclerotic disease, this result reinforces the idea
of the potential use of OPN and Angpt-2 as biomarkers to
predict CV risk in patients with AS.
As previously mentioned, a single infusion of the anti-
TNF-𝛼 monoclonal antibody infliximab led to a significant
reduction in Angpt-2 serum levels in our series of AS patients
[99]. Likewise, a single infusion of infliximab also triggered a
decrease in OPN serum levels in our cohort of AS patients
[107]. This is in accordance with the proinflammatory role
proposed for these biomarkers of endothelial cell activation
and atherosclerosis and the beneficial effect against the
development of CV disease mediated by the use of anti-TNF-
𝛼 therapy.
4.4. Gelsolin (GSN). Gelsolin (GSN) is an anti-inflammatory
protein mainly secreted by muscle cells, that is, involved in
cytoskeleton reorganization [108]. GSN acts by binding to
actin filaments (and probably to other extracellular matrix
components) and thus prevents the activation of downstream
inflammatory pathways by these filaments [109]. Reduced
GSN levels have been reported in situations of acute injury
or inflammation [109–111]. In this regard, it was proposed
that in inflammatory diseases such as RA, circulating GSN
may be potentially locally consumed by the interaction with
macromolecules such as actin, fibrin, and fibronectin at the
joints or other affected organs, leading thus to a reduction
of the levels of GSN [109]. In keeping with these findings
we observed lower levels of GSN in AS patients undergoing
anti-TNF-𝛼 therapy when compared to healthy controls [112].
These data support the potential function of GSN as an anti-
inflammatory molecule.
As observed for other biomarkers and adipokines, a
single infusion of anti-TNF-𝛼 infliximab did not produce any
significant change on GSN serum levels in our AS patients
[112]. As pointed out before, a possible explanation for this
steady level of GSN might be the low disease activity of our
patients, since they had been receiving infliximab for a long
period of time.
4.5. Osteoprotegerin (OPG). Osteoprotegerin (OPG) is a
member of the TNF receptor superfamily, that is, implicated
both in osteoporosis and in the atherosclerotic process.
OPG acts as a decoy receptor for the receptor activator of
nuclear factor-𝜅B ligand (RANKL), inhibiting binding of
RANKL to its receptor, RANK [113, 114]. OPG also acts as
a soluble neutralizing receptor of TNF-related apoptosis-
inducing ligand (TRAIL), an anti-inflammatory molecule
with antiatherosclerotic properties [115–117]. Furthermore, it
has been reported that OPG can upregulate the production of
endothelial adhesion molecules [118].
OPG has previously been associated with increased
risk of atherosclerotic disease in the general population
[119]. Interestingly, a recent study of our group on patients
with RA undergoing infliximab therapy disclosed that
OPG concentrations were associated with biomarkers of
endothelial activation (intercellular adhesion molecule-1),
carotid intima-media wall thickness, and carotid plaques
[120]. In keeping with these results, in our series of AS
patients undergoing infliximab therapy we have disclosed
an independent correlation with ADMA, another biomarker
of endothelial cell activation [121]. This further supports
the role of OPG as a valuable CV disease risk biomarker
in chronic inflammatory rheumatic diseases such as
AS.
Although a significant reduction of OPG levels upon
infusion of this biologic agent was recently reported in long-
standing RA patients with severe disease undergoing anti-
TNF-𝛼 therapy [120], a single administration of anti-TNF-
𝛼 infliximab did not lead to any significant reduction of
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OPG levels in our series of AS patients [121]. The low disease
activity and low inflammatory burden observed at the time of
the study in our series of AS patients could probably explain
the lack of significant reduction of OPG levels following
administration of anti-TNF-𝛼.
5. Therapeutic Potential Applications of
These Biomarkers and Adipokines
Constantly, a progressively increasing list of new potential
biomarkers and adipokines comes out, being subject to eval-
uation for their involvement in CV disease or MeS. However,
as wisely suggested by other authors, these molecules exert
such complex physiological effects that their use as potential
therapeuticmoleculesmust be carefully planned to obtain the
adequate result and to avoid unknown side effects [5, 40].
Another point of potential interest is the possible use of
these molecules as biomarkers of CV disease and predictors
of increased risk for CV events or MeS in patients with
diseases like AS that are associated with increased risk of
CV death. However, up to now the routine use of these
biomarkers in the daily clinical practice is still far from being
well established. It is applicable not only to individuals with
chronic inflammatory rheumatic diseases like AS or RA but
also to the general population.
6. Conclusions
The assessment of adipokines and biomarkers of endothelial
cell activation and MeS may be of potential interest for the
improvement of the stratification of the CV risk of patients
with AS. However, further studies are still needed to fully
elucidate the clinical implication of these molecules in the
mechanisms leading to accelerated atherosclerosis in AS and
the benefits of the assessment of these molecules in the daily
clinical practice.
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arthritis synovial tissue, synovial fluid and serum,”Annals of the
Rheumatic Diseases, vol. 66, no. 4, pp. 458–463, 2007.
[44] M. A. Gonzalez-Gay, M. T. Garcia-Unzueta, C. Gonzalez-
Juanatey et al., “Anti-TNF-𝛼 therapy modulates resistin in
patients with rheumatoid arthritis,” Clinical and Experimental
Rheumatology, vol. 26, no. 2, pp. 311–316, 2008.
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